Legend Biotech Corp
LEGN · XNASCIK 1801198fmd_0NATSPTZ8TSMPARA9R1Y716FKXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2025, 21 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 49 | 60 | 75 | 69 | 117 | 285 | 627 | 1,029 |
| Cost of revenue | – | – | 0 | 0 | 65 | 144 | 216 | 397 |
| Gross profit | – | – | 75 | 69 | 52 | 141 | 411 | 632 |
| Research and development | 61 | 162 | 232 | 313 | 336 | 382 | 414 | 415 |
| Operating income | – | – | – | – | – | (528) | (310) | (137) |
| Interest expense | 0 | 0 | 4 | 1 | 11 | 22 | 22 | 21 |
| Income before taxes | (2) | (127) | (308) | (407) | (446) | (520) | (158) | (283) |
| Income tax expense | 1 | (26) | (42) | (4) | 1 | (2) | 19 | 14 |
| Net income from continuing operations | (3) | (102) | (266) | (404) | (446) | (518) | (177) | (297) |
| Net income | (3) | (102) | (266) | (404) | (446) | (518) | (177) | (297) |
| Net income to common shareholders | – | – | – | – | (446) | (518) | (177) | – |